Can Recurrence of Cancer in the Oropharynx Be Detected by Blood Samples?
Launched by RIGSHOSPITALET, DENMARK · Sep 10, 2024
Trial Information
Current as of June 26, 2025
Recruiting
Keywords
ClinConnect Summary
This clinical trial is exploring whether blood tests can help doctors detect if oropharyngeal cancer, specifically HPV-positive squamous cell carcinoma, comes back after treatment. The researchers want to see if analyzing tiny pieces of HPV DNA found in the blood can provide early signs of cancer recurrence, which is when the cancer returns after it has been treated.
To participate in this study, you need to be an adult over 18 years old who has been newly diagnosed with HPV-positive oropharyngeal cancer and is receiving treatment aimed at curing the disease. If you choose to join, you will provide blood samples that will be analyzed throughout your treatment, and your participation will help researchers learn more about the potential of using blood tests for monitoring cancer recurrence. Please note that only Danish-speaking individuals can participate, and those with other significant health conditions may be excluded from the study.
Gender
ALL
Eligibility criteria
- Inclusion Criteria:
- • Patients with newly diagnosed HPV+ (or p16+) OPSCC carcinoma originating from the oropharynx
- • Above 18 years of age
- • Informed consent
- • Patients offered curative treatment.
- Exclusion Criteria:
- • The patient does not speak or understand Danish
- • The patient has another disease/condition considered a reason for exclusion
About Rigshospitalet, Denmark
Rigshospitalet, located in Copenhagen, Denmark, is one of the leading hospitals in Scandinavia and a prominent center for clinical research and innovation. As a key academic institution affiliated with the University of Copenhagen, Rigshospitalet is dedicated to advancing healthcare through rigorous clinical trials and groundbreaking research across various medical disciplines. The hospital’s commitment to excellence is reflected in its multidisciplinary approach, collaboration with international research networks, and focus on improving patient outcomes through evidence-based practices. With state-of-the-art facilities and a team of highly qualified professionals, Rigshospitalet plays a crucial role in translating scientific discoveries into effective treatments and therapies.
Contacts
Jennifer Cobb
Immunology at National Institute of Allergy and Infectious Diseases (NIAID)
Locations
Copenhagen, , Denmark
Patients applied
Trial Officials
Christian von Buchwald, Professor, MD, DMSci
Study Chair
Department of Otorhinolaryngology, Head and Neck Surgery and Audiology, Rigshospitalet
Timeline
First submit
Trial launched
Trial updated
Estimated completion
Not reported